Clinical Trials Sponsored by Nordic Myeloma Study Group, Germany

Total 147 results

Nordic Myeloma Study Group

Completed

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Multiple Myeloma

Denmark, Sweden, Norway
Nordic Myeloma Study Group

Unknown

Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients

Multiple Myeloma

Denmark
Nordic Myeloma Study Group
Nordic Cancer Union

Completed

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Multiple Myeloma

Denmark, Norway, Sweden
Oslo University Hospital
Nordic Myeloma Study Group

Active, not recruiting

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. (CONPET)

Myeloma

Norway, Denmark, Sweden
Nordic Myeloma Study Group
Janssen-Cilag Ltd.

Completed

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Multiple Myeloma

Norway, Sweden, Denmark, Finland, Iceland
Nordic Myeloma Study Group
Janssen-Cilag Ltd.

Unknown

Bortezomib and High-dose Melphalan at Myeloma Relapse

Multiple Myeloma

Denmark, Norway, Sweden
West German Study Group
AGO Germany

Completed

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Breast Cancer

Germany
Henrik Gregersen
Nordic Myeloma Study Group

Unknown

Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support (CARFI)

Multiple Myeloma

Finland, Denmark, Sweden, Norway, Lithuania
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
Norwegian University of Science and Technology
The Research Council of Norway; Nordic Myeloma Study Group, Germany

Completed

Thalidomide to Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma

Norway
Odense University Hospital
Danish Myeloma Study Group

Active, not recruiting

Quality of Life the Danish Multiple Myeloma Patients (QoL-MM)

Quality of Life | Multiple Myeloma

Denmark
Raija Silvennoinen
Takeda; Celgene; Nordic Myeloma Study Group

Active, not recruiting

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

Multiple Myeloma

Norway, Sweden, Finland, Lithuania
Stichting Hemato-Oncologie voor Volwassenen Nederland
German CLL Study Group; Nordic CLL Study Group

Recruiting

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER)

CLL/SLL

Netherlands, Denmark, Belgium, Germany
German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
West German Study Group

Active, not recruiting

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (ADAPT)

Breast Cancer

Germany
West German Study Group

Active, not recruiting

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (ADAPT)

Breast Cancer

Germany
German CLL Study Group

Completed

Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Recruiting

Registry of the German CLL Study Group (CLL-Registry)

CLL | Leukemia, Prolymphocytic, T-Cell | SLL | Leukemia, Prolymphocytic, B-Cell | HCL | T-LGL Leukemia | Richter´s Transformation | NK-LGL Leukemia

Germany
German CLL Study Group

Completed

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

France, Germany, Austria
German CLL Study Group

Completed

Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia

Anemia | Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia

Canada, Germany
German CLL Study Group

Terminated

Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

T-Cell Large Granular Lymphocytic Leukemia

Germany
German CLL Study Group

Terminated

Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
German CLL Study Group

Terminated

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany
German CLL Study Group

Active, not recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG)

Chronic Lymphoid Leukemia

Germany
German CLL Study Group

Active, not recruiting

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)

Chronic Lymphoid Leukemia

Austria, Germany
German CLL Study Group

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL (CLL2-BAAG)

Chronic Lymphoid Leukemia

Germany
German CLL Study Group

Completed

Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Chronic Lymphocytic Leukemia

Germany
Oslo University Hospital
Helse Stavanger HF; St. Olavs Hospital; Nordic Myeloma Study Group

Active, not recruiting

REST - Replacing Steroids in the Transplant Ineligble (REST)

Multiple Myeloma

Norway, Denmark
German Breast Group
AGO Study Group

Completed

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Breast Cancer

Germany
German Breast Group
AGO Study Group

Completed

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

Breast Cancer

Germany
West German Study Group
AstraZeneca

Not yet recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)

HER2-positive Early Breast Cancer

Germany
West German Study Group
Agendia

Recruiting

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS (PROOFS)

Female Breast Cancer

Germany
German CLL Study Group
AstraZeneca

Recruiting

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Chronic Lymphocytic Leukemia

Germany
West German Study Group
Celgene

Active, not recruiting

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer (ADAPT)

Breast Cancer

Germany
German CLL Study Group
Celgene

Completed

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Chronic Lymphocytic Leukemia

Germany
West German Study Group
GlaxoSmithKline

Terminated

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Carcinoma, Ductal, Breast

Germany
West German Study Group
Agendia

Completed

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe) (PRIMe)

Breast Cancer

Switzerland, Austria, Germany
German Parkinson Study Group (GPS)

Completed

STN-Stimulation Versus Best Medical Treatment in Advanced PD

Parkinson's Disease

Germany
Henrik Gregersen
Danish Myeloma Study Group

Terminated

Clarithromycin in Multiple Myeloma Induction Therapy (CLAIM)

Multiple Myeloma

Denmark
Henrik Gregersen
Danish Myeloma Study Group

Unknown

Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma (SUTRICA)

Multiple Myeloma | Infection

Denmark
Gilead Sciences
German CLL Study Group

Completed

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Gilead Sciences
German CLL Study Group

Completed

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany

3

Subscribe